Protein-tyrosine kinases (PTKs) were first identified as transforming proteins encoded by a class of retroviruses. These viral proteins represent an altered form of cellular enzymes strongly conserved throughout evolution (for a review, see reference 11) . Although the biological function of cellular PTKs remains largely unknown, they are suspected of playing a crucial role in signal transduction pathways. One striking feature of these proteins is their high degree of amino acid sequence homology within the kinase domain. Despite this sequence conservation, PTKs display varied biological functions. The functions of growth factor receptors that have cytoplasmic PTK domains, like those for epidermal growth factor, insulin, and platelet-derived growth factor, are obviously different. These functional differences reflect more than their ligand-binding specificity, because platelet-derived and epidermal growth factors trigger quite distinct biochemical responses in cells that have both receptors on their surface (14) . That can only be accomplished if the activated receptor kinases display different substrate specificities. Little is known about what sequences in these molecules are involved in directing such specificities, except that they are within the cytoplasmic region.
To address the question of structure-function relationships in these proteins and other tyrosine kinases, we chose the v-abl and v-src oncogenes as models. These oncogenes are highly related in amino acid sequences (26, 30, 32) , but have distinct biological properties (10, 17, 19, 27, 29) . Abelson murine leukemia virus (A-MuLV) (v-abl) transforms both fibroblasts and lymphoid cells in vitro (27, 29) and relieves interleukin 3 (IL-3)-dependent cells of their growth factor requirement (5, 19, 21, 23) . Rous sarcoma virus (v-src) transforms fibroblasts, but only causes lymphoid transformation and IL-3 independence poorly if at all (10, 17, 19, 22) . These differences are clearly a function of the oncogenes proper: placing v-src in a structural configuration resembling that of v-abl in A-MuLV failed to duplicate the biological properties of A-MuLV or other viruses carrying the v-abl * Corresponding author.
oncogene (17, 19) . To identify sequences responsible for these biological differences and implicitly responsible for substrate specificity, we recombined v-abl and v-src just downstream of the lysine in the ATP-binding sites (12) , within the kinase domain. The chimeric genes were characterized biochemically and their biological activity was compared with that of v-abl and v-src.
MATERIALS AND METHODS
Cells, virus, and transfection. Normal and transformed NIH 3T3 fibroblasts were grown in Dulbecco modified Eagle medium with 10% calf serum. Bone marrow cells, obtained from tibias and femurs of 3-week-old BALB/c mice, were cultured in RPMI medium containing 10% fetal calf serum and 50 ,uM 3-mercaptoethanol. Ba/F3 cells (19) were grown in RPMI medium with 10% fetal calf serum and 10% WEHI-3 cell-conditioned medium (as a source of IL-3). V-SRC virus and Moloney murine leukemia virus (Mo-MuLV) have been described (17) . Titers of the various viruses were determined by focus assay on NIH 3T3 cells. Infection of bone marrow cells was performed in liquid cultures as described (27) . Transfections and screening of focus formation were done as described (17) .
Antisera and protein biochemistry. Tumor-bearing rabbit antiserum (derived against Rous sarcoma virus strain D proteins) a-VBII and anti-gag protein antiserum have been described (17) . Anti-abl 584 antiserum (33) was a gift from J. Wang. Anti-src monoclonal antibody MAb327 (15) was a gift from J. Brugge. Cell extracts, immunoprecipitations,
[35S]methionine labeling, and in vitro kinase reactions were performed as described (18) . When warranted, changes in these procedures have been indicated in the text. Glycerol gradients were run by the method of Buss et al. (4) . Fractions were collected from the top. Polyacrylamide gel electrophoresis was done by the procedure of Laemmli (13) . Gels (7.5 or 8.5% acrylamide) were run at constant voltage.
Mutagenesis and plasmid construction. The point mutation in v-src was obtained by site-directed mutagenesis with a specific oligonucleotide. The 260-base-pair (bp) PstI fragment of v-src, containing the site to be mutated, was sub-cloned in M13mp8. The proper orientation of the fragment was ensured by sequencing. The 19-mer oligonucleotide 5'-CCTCCGGGGCCATGGTGCC-3' was obtained from the Whitehead Institute oligonucleotide synthesis facility. Annealing of the oligonucleotide and M13 universal template primer to M13 template containing the PstI fragment and repair-ligation reactions and screening of mutagenized clones were performed as described (37). The T-to-G transversion was confirmed by the creation of a novel NcoI site within the PstI fragment and independently by sequencing.
pV-SRCneo plasmid. pV-SRC plasmid DNA (17) was cut with KpnI (unique site in the long terminal repeats [LTRs] ). The v-src-containing fragment was cloned in pUC-ABX2 (see below), similarly cut with KpnI. This intermediate was then cut with MluI and StuI. These sites are unique in the PstI fragment of v-src used for mutagenesis and lie on either side of the planned mutation (30, 32) . The M13 clone containing the mutagenized v-src fragment was also cut with MluI and StuI; the small v-src fragment (now containing an NcoI site) was recloned in the doubly digested pUC intermediate (described above) to yield pV-SRCnco plasmid (see Fig. 2 ).
pUC-ABX2 plasniid. To create the pUC-ABX2 plasmid (referred as pABX2 in the text), the ABX2 plasmid (25) was modified as follows. Rat sequences flanking the 5' and 3' LTRs of ABX2 provirus were trimmed by digesting with HincII (partial) and BstEII (complete). The new ends were converted into an HindIII site (5') and EcoRI site (3'). The provirus was then subcloned in the polylinker of the pUC13 plasmid (see Fig. 2 ).
pV-ARC plasmid. pABX2 plasmid DNA was cut with NcoI and HindIII, and the large fragment was isolated. pV-SRCnco plasmid DNA was similarly cut with NcoI and HindIII, and the small v-src-containing fragment was ligated to the large fragment isolated above (see Fig. 2 ).
pV-SBL plasmid. pV-SRCnco plasmid DNA was cut with NcoI and HindIII. The larger fragment containing the 5' half of v-src was isolated. pABX2 was cut with NcoI and HindIII, and the smaller fragment was ligated to that isolated above (see Fig. 2 ).
RESULTS
To identify the sequences that distinguish the biological activity of v-abl from that of v-src, we created reciprocal recombinants between the two genes and studied how the v-abl phenotype segregated in each recombinant. For this purpose, a region just downstream of the lysine in the ATP-binding site of v-abl and v-src was chosen for recombination (Fig. 1) . In v-abl, an NcoI site (CCATGG) is present, whereas the corresponding sequence in v-src (based on amino acid alignment) is CCATGT. We used oligonucleotide-directed mutagenesis to make a T-to-G transversion in the above v-src hexamer sequence. This created an NcoI site in v-src and replaced a serine residue with an alanine residue (Fig. 1) . The entire v-src gene, containing the mutated fragment, was reconstructed and inserted back into a murine retroviral vector. This construct, pV-SRCnco, was cotransfected with helper virus Mo-MuLV plasmid DNA (pZAP) into NIH 3T3 cells, and its activity was compared with that of the wild-type construct, pV-SRC. We observed no differences in efficiency or time of focus appearance. Furthermore, viral stocks prepared from cells transfected with pV-SRCnco or pV-SRC showed comparable titers (data not shown). The transforming protein detected in pV-SRCnc'-transformed cells displayed a high level of in vitro tyrosine kinase activity (see Fig. 4 , lane a). It also comigrated with wild-type p60vsrc during electrophoresis through a sodium dodecyl sulfate (SDS)-polyacrylamide gel (data not shown).
Because pV-SRCnco was biologically active and behaved identically to pV-SRC, we proceeded with the recombination outlined in Fig. 2 . Parental DNAs, pV-SRCnco, and pABX2 were recombined at the NcoI site to yield two reciprocal constructs, pV-SBL (srclabl) and pV-ARC (abllsrc). These constructs were tested for biological activity on NIH 3T3 cells. DNAs were cotransfected into these cells with pZAP DNA (Mo-MuLV helper DNA) and pSV2neo (which confers G418 resistance [31] ) DNAs. Two days later, cells were split into two sets; one set was selected in the presence of G418, and the other was checked for the appearance of foci. Parental DNAs (pV-SRCnco and pABX2) were transfected by the same protocol. Foci were observed simultaneously in pV-SRCnco, pABX2, and pV-SBL cultures. We did notice a slight decrease (three-to fivefold) in the number of foci with pV-SBL compared with pABX2 (data not shown). Surprisingly, we detected no foci in pV-ARC cultures. When G418-resistant colonies were scored, we saw equivalent numbers of colonies in pVSRCnco and pV-ARC cultures. A dramatic reduction in number was evident in pABX2 and pV-SBL plates. Whereas the vast majority of pV-SRCnc, colonies were transformed (over 90%), none of the pABX2 or pV-SBL G418-resistant colonies were. This is usually observed with plasmids that produce A-MuLV and results from a toxic effect of v-abl on transfected cells (36) . Foci seen in unselected cells result from the spread of infectious virus transiently expressed in cells cotransfected with v-abl and pZAP plasmid DNAs. These results indicate that, in fibroblasts, pV-SBL behaves similarly to pABX2, whereas pV-ARC is transformation defective. To examine whether pV-ARC might cause temperature-sensitive transformation, we placed the G418-resistant colonies or unselected cultures at 32 or 39°C. This had no effect on cell morphology in either set of plates, even after a prolonged incubation of 5 days.
To obtain virus stocks and check for synthesis of the viral chimeric proteins, we obtained cell clones from each of the transfected cultures. pV-SRCnco, pABX2, pV-SBL, and pV-ARC cell clones and uninfected NIH 3T3 cells were then labeled with [35S]methionine, and cell extracts were made. Portions were immunoprecipitated with a battery of specific antisera which recognized gag (a-gag), v-src (aVBII, MAb327), or v-abl (a-584) determinants. pV-SBL-directed protein has a predicted molecular mass of 89 kilodaltons Fig. 5 ) were 90 and 50 kDa in mass (faint in this figure) . These proteins were also observed when a-VBII was used (Fig. 3C) . In all likelihood, they are the two cellular proteins, hsp90 and p50, previously described as forming a specifice &mplex with p6`v'src and some other src-related proteins (2) . Evidence for such a complex with the pV-ARCencoded protein, P68"c, is provided below.
The same extracts were reacted with a-abl antiserum (Fig.  3B, lanes a to c) or MAb327 (a-src) (lanes d to f). pljfgag-abI was readily detected, as well as its glycosylated form (35) , which runs more slowly (lane a; also seen in lane c, Fig. 3A) . To test whether the viral chimeric proteins exhibited PTK activity, extracts from unlabeled cell clones were immunoprecipitated and immune complexes were assayed for in vitro kinase activity. Transforming proteins of pV-SRCnco, pABX2, and pV-SBL were all autophosphorylated in this assay (Fig. 4) investigated further. For the pV-ARC extracts, very little radioactivity was detected in association with P68arc (data not shown).
The apparently very low kinase activity of P68"' could explain the failure of V-ARC virus to transform fibroblasts. To investigate its activity more precisely, V-ARC-and ABX2-infected fibroblasts were labeled for 18 h with [355] methionine, and levels of P68"' and pjOOgag-abl were analyzed after immunoprecipitation with anti-gag antiserum (Fig. 5A) . Because we detected similar amounts of both proteins after this long labeling period, we could exclude the possibility that P68"tC expression was too low to achieve transformation of fibroblasts. When plWfgag-abl and P68a', immunoprecipitated from identical portions of the lysates shown in Fig. 5A , were compared for their ability to phosphorylate in vitro the exogenous substrate a-casein, P68arc showed 23-fold lower activity (Fig. 5B) . A 26-fold lower activity was measured when enolase was used as a substrate (data not shown). Thus, the defectiveness of V-ARC virus is best explained by the low specific PTK activity of P68arc.
As noticed previously, P68arc was recovered in association with two cellular proteins presumed to be hsp90 and p50. To for 14 h, and a clarified lysate was centrifuged through a glycerol gradient. Fractions were collected and analyzed by SDS-polyacrylamide gel electrophoresis after immunoprecipitation with a-gag antiserum (Fig. 6) . The free form of P68arC would be found in the same fractions as Pr659ga and the "gag-related" 58-kDa proteins which migrate as monomers. It is clear from this analysis, however, that P68atC protein did not sediment as a monomer; rather, the majority sedimented as a much larger species and cosedimented with 50-and 90-kDa proteins. Thus, nearly all of P68a was bound up in a complex with the two cellular proteins hsp90 and p50. Interestingly, we were unable to detect plgag-abl, even transiently, in a similar complex (data not shown).
As a final biochemical characterization of the chimeric proteins, we examined their divalent cation requirement in the in vitro kinase reaction. Immune complexes containing the pV-SRC, pV-SRCnco, pABX2, or pV-SBL transforming protein were suspended in kinase buffer containing either 10 mM Mg2+, 10 mM Mn2+, or no divalent cations. Very little activity was detected (less than 1%) for all proteins in the absence of divalent cations (data not shown). p6V-src encoded by pV-SRC, demonstrated a slight preference for Mn2+ over Mg2+ in this assay (Table 1) . Surprisingly, p60v-src encoded by pV-SRCnco showed a marked preference for Mn2+. This difference is probably a consequence of the fact that the mutation introduced in pV-SRCnco is so close to the ATP-binding site (Fig. 1) . Likewise, P89sb1 showed higher activity when Mn2+ was present in the assay. plOOgag-abl also preferred Mn2+, but the difference was not as marked (Table 1) .
To examine the effects of the various viruses on lymphoid and Ba/F3 cells ( as expected, was transformation defective on fibroblasts, but the V-ARC genome was passed at good efficiency, as measured by expression of the predicted protein in freshly infected cells (data not shown).
To study the effect of these viruses on bone marrow cell transformation, cells collected from the femurs and tibias of 3-week-old mice were infected in liquid cultures with each viral stock, as well as with Mo-MuLV and V-SRC viruses. V-ARC and Mo-MuLV viruses had no effect on the bone marrow cultures. V-SRC and V-SRCnco viruses caused a transient burst of proliferation in the infected cultures. We were unable, however, to recover any transformed cells, even 3 months after infection and cultivation of the cells over a bone marrow-derived feeder layer. ABX2 and V-SBL viruses, by contrast, elicited continuous proliferation of suspension cells at equal efficiency. Transformed cells were established in the absence of feeder cells 3 weeks after infection. We confirmed that cells transformed with V-SBL virus synthesized P89sbl protein (Fig. 3D, lane b) . We also found that these cells had rearranged their immunoglobulin genes in a configuration typical of pre-B cells (8) (data not shown). Thus, in this assay, V-SBL virus behaved identically to ABX2 virus.
The above viruses were next used to infect Ba/F3 cells. These cells are early lymphoid precursor cells that require IL-3 for growth in vitro. v-abl transformation confers IL-3 independence on Ba/F3 cells, whereas v-src transformation (17, 19) . However, both oncogenes are very efficient at transforming fibroblasts (10, 17, 29 (12) . By recombining v-src and v-abl downstream of this lysine, we ensured that V-ARC received the majority of its kinase from v-src and V-SBL received the equivalent region from v-abl. They received about 40 and 30 kDa, respectively, of the N-terminal amino acid sequence from the other partner. This sequence contains regions of v-srclv-abl homology but is much less homologous than the kinase region and might have been thought to encode the transformation specificity.
The virus carrying the v-srclv-abl oncogene, V-SBL, behaved biologically like ABX2 virus (or A-MuLV). It transformed fibroblasts and lymphoid cells in vitro and rendered Ba/F3 cells IL-3 independent. The efficiency of V-SBL and ABX2 viruses in eliciting these effects was similar, but a small decrease in focus formation after transfection of pV-SBL DNA was noted.
Thus, the v-abl sequence present in V-SBL virus appears to induce effects usually ascribed to the entire v-abl sequence. Unfortunately, the behavior of V-ARC virus was not reciprocal to that of V-SBL; rather, V-ARC virus was transformation defective. This lack of transformation correlated with two biochemical findings. V-ARC protein had very low specific kinase activity, and the majority of the protein was recovered as a complex with two cellular proteins, hsp9O and p50 (2) . The reason for the complex formation is not known. Perhaps the two cellular proteins recognize in P68arc an unproperly folded molecule and sequester it, in a complex, away from the plasma membrane. Alternatively, P68arc protein may lack sequences normally involved in releasing p60v-src from the complex with p50 and hsp90. We tested this possibility by replacing the gag sequences of P68arc with the first 110 amino acids of p60vsrc. The gag and N-terminal src sequences had been shown previously to be interchangeable in chimeric constructs (17) . This replacement, however, failed in releasing the new chimeric protein from its complex. It also resulted in a transformation-defective protein with low kinase activity (data not shown). Also unresolved is the reason for the low kinase activity of P68"rc. It could be either an intrinsic enzymatic defect or the consequence of sequestration of the protein in a complex. Previously, it had been reported that the kinase activity of p6vsrc complexed to p50 and hsp90 is significantly reduced (3, 6) , but this view has recently been challenged (9) .
Regardless of these open questions, our results demonstrate two significant points. Despite the lack of relevant information about the three-dimensional structure of p60v-src or plOOgag-abl to suggest a recombination site, we did suc- These experiments show that induction of IL-3 independence and transformation of lymphoid cells both correlate with the sequences common between V-SBL and ABX2 viruses, mainly the PTK domain. The fact that V-ARC virus is transformation defective is noninformative in this respect. Recently, Privalsky (24) fused the first 119 N-terminal amino acids of v-erbB to amino acids 226 to 526 of v-src. The chimeric gene induced fibroblast transformation and expressed a hybrid protein with biochemical characteristics similar to those of v-src (24) . The chimera failed, however, in transforming erythroid cells. Thus, target cell specificity of v-src was not influenced by the v-erbB sequence present in the hybrid. Erythroid transformation therefore appears to require v-erbB sequences encoded in the kinase domain of this oncogene.
The common sequences between V-SBL and ABX2 viruses do extend downstream of the v-src homology in v-abl. These additional sequences are not in the kinase domain proper and might also contribute to the biological properties of these viruses. In fact, the region downstream of the kinase domain of v-abl in A-MuLV has been linked in vitro to enhanced lymphoid transforming ability by this virus and in vivo to enhanced tumorigenicity (28) . This finding does not, however, indicate that sequences beyond the PTK domain are necessary for lymphoid transformation, because certain variants of an A-MuLV strain which lack most of these 3' sequences, although crippled in their ability to transform lymphoid cells in vitro, can induce lymphomas in vivo with an efficiency comparable to that of wild-type A-MuLV (20) . Even though important interactions are likely to be mediated by this sequence, the region appears to serve as a modulator of the intrinsic biological properties of the v-abl kinase domain. The existence of complex interactions within the v-abl sequences should not obscure the main conclusion of these experiments: the transformation specificity of a viral PTK has been localized to a region that is coincident with the center of catalytic activity, implying that it is probably catalytic specificity which determines transformation specificity.
